XORTX Therapeutics Inc.

NasdaqCM:XRTX Stock Report

Market Cap: US$4.0m

XORTX Therapeutics Management

Management criteria checks 3/4

XORTX Therapeutics' CEO is Allen Davidoff, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $321.96K, comprised of 79.2% salary and 20.8% bonuses, including company stock and options. directly owns 2.37% of the company’s shares, worth $94.75K. The average tenure of the management team and the board of directors is 2.9 years and 4.1 years respectively.

Key information

Allen Davidoff

Chief executive officer

US$322.0k

Total compensation

CEO salary percentage79.2%
CEO tenure6.8yrs
CEO ownership2.4%
Management average tenure2.9yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

XORTX completes positive pre-phase 3 meeting with the FDA

Sep 19

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

Aug 22

XORTX jumps over 100% after early encouraging data for rare disease therapy

Jul 13

CEO Compensation Analysis

How has Allen Davidoff's remuneration changed compared to XORTX Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$737k

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

-US$3m

Dec 31 2023US$322kUS$255k

-US$2m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$7m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$321kUS$273k

-US$8m

Sep 30 2022n/an/a

US$1m

Jun 30 2022n/an/a

-US$3m

Mar 31 2022n/an/a

-US$2m

Jan 01 2022n/an/a

-US$2m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$204kUS$154k

-US$1m

Sep 30 2020n/an/a

-US$767k

Jun 30 2020n/an/a

-US$536k

Mar 31 2020n/an/a

-US$362k

Dec 31 2019US$161kUS$148k

-US$485k

Sep 30 2019n/an/a

-US$444k

Jun 30 2019n/an/a

-US$582k

Mar 31 2019n/an/a

-US$660k

Dec 31 2018US$194kUS$141k

-US$3m

Compensation vs Market: Allen's total compensation ($USD321.96K) is below average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: Allen's compensation has increased whilst the company is unprofitable.


CEO

Allen Davidoff (64 yo)

6.8yrs

Tenure

US$321,959

Compensation

Dr. Allen Warren Davidoff, Ph.D. is Founder of XORTX Therapeutics Inc. (formerly known as XORTX Pharma Corp.) and has been its Chief Executive Officer and President since January 9, 2018. Dr. Davidoff serv...


Leadership Team

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder6.8yrsUS$321.96k2.37%
$ 94.8k
James Fairbairn
Chief Financial Officer1.4yrsUS$57.51k0.22%
$ 8.6k
Stephen Haworth
Chief Medical Officer3.3yrsUS$173.37k0%
$ 0
Stacy Evans
Chief Business Officer2yrsUS$211.33kno data
Nick Rigopoulos
Director of Communicationsno datano datano data
David Sans
Director of Corporate Development4.3yrsno datano data
David MacDonald
Consultant of Clinical Operations2.5yrsno datano data
Charlotte May
Corporate Secretaryno datano datano data

2.9yrs

Average Tenure

60.5yo

Average Age

Experienced Management: XRTX's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder6.8yrsUS$321.96k2.37%
$ 94.8k
Paul Van Damme
Independent Director6.8yrsUS$8.20k0.22%
$ 8.8k
Anthony Giovinazzo
Independent Chair of the Board2.4yrsUS$101.11k0.30%
$ 11.9k
Richard Johnson
Member of Clinical Advisory Boardno datano datano data
William Farley
Independent Director3.5yrsUS$7.87k0%
$ 0
Raymond Pratt
Independent Director2.9yrsUS$7.37k0%
$ 0
Henk E. D. ter Keurs
Member of Scientific Advisory Boardno datano datano data
Federico Maese
Member of Clinical Advisory Board6.1yrsno datano data
Patrick Treanor
Independent Directorless than a yearno data0%
$ 0
Petter Bjornstad
Member of Clinical Advisory Board6.1yrsno datano data
Anjay Rastogi
Member of the Clinical Advisory Board4.7yrsno datano data
Charles Edelstein
Member of the Advisory Board3.3yrsno datano data

4.1yrs

Average Tenure

68.5yo

Average Age

Experienced Board: XRTX's board of directors are considered experienced (4.1 years average tenure).